{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:07:50Z","timestamp":1788847670343,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and dose-limiting toxicity of nab-paclitaxel in breast cancer patients. Severe CIPN can impair quality of life, limit treatment adherence, and lacks validated prediction tools for early risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify risk factors for grade \u22653 CIPN in breast cancer patients treated with nab-paclitaxel and to develop a predictive model for individualized risk assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study using clinical data from January 2021 to January 2025. Predictors were selected with least absolute shrinkage and selection operator (LASSO) regression and included in multivariable logistic regression. A nomogram was constructed, and model performance was evaluated using area under the curve (AUC), Hosmer-Lemeshow test, calibration curve, and decision curve analysis. Restricted cubic spline analysis examined nonlinear associations of body mass index (BMI) and total bilirubin (TBIL) with CIPN risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Mianyang Central Hospital, a tertiary referral center in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      A total of 403 breast cancer patients receiving nab-paclitaxel. Among them, 13.2% (53\/403) developed CIPN \u2265 Grade 3. Patients with severe CIPN more frequently had higher BMI, elevated TBIL, smoking or alcohol drinking, and diabetes, and lower platelet count, total protein, and hemoglobin (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcomes and measures<\/jats:title>\n                    <jats:p>Occurrence of CIPN \u2265 Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LASSO identified BMI, TBIL, smoking, alcohol drinking, and diabetes as key predictors. All were confirmed as independent risk factors in multivariable analysis, with diabetes showing the strongest association (adjusted OR = 4.01). The nomogram demonstrated good discrimination (AUC = 0.78), calibration (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.898), and clinical utility. Restricted cubic spline analysis showed a linear association between TBIL and CIPN risk, and significantly increased risk with BMI \u226524\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and relevance<\/jats:title>\n                    <jats:p>Elevated BMI, smoking, Alcohol drinking, diabetes, and TBIL are independent risk factors for severe CIPN in patients with breast cancer treated with nab-paclitaxel. The proposed nomogram may support early identification of high-risk patients and guide individualized prevention and management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1794696","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:35:35Z","timestamp":1788845735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk prediction of severe chemotherapy-induced peripheral neuropathy in breast cancer patients receiving nab-paclitaxel: a clinical nomogram"],"prefix":"10.3389","volume":"17","author":[{"given":"Yujun","family":"Tong","sequence":"first","affiliation":[{"name":"Department of Breast Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Liang","sequence":"additional","affiliation":[{"name":"Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangping","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Guangyuan Central Hospital","place":["Guangyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1111\/jdi.13568","article-title":"Bilirubin is inversely related to diabetic peripheral neuropathy assessed by sural nerve conduction study","volume":"12","author":"Abe","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3390\/cancers17081271","article-title":"Synergy of body composition, exercise oncology, and pharmacokinetics: a narrative review of personalizing paclitaxel treatment for breast cancer","volume":"17","author":"Adriaenssens","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1634\/theoncologist.2018-0298","article-title":"Age and the risk of paclitaxel-induced neuropathy in women with early-stage breast cancer (alliance A151411): results from 1,881 patients from cancer and leukemia group B (CALGB) 40101","volume":"24","author":"Barginear","year":"2019","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3390\/antiox11091632","article-title":"Bilirubin 2022: the past, the present and the future","volume":"11","author":"Bellarosa","year":"2022","journal-title":"Antioxidants (Basel, Switz)."},{"key":"B5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/1521-4141(200108)31:8<2448::aid-immu2448>3.0.co;2-n","article-title":"The role of MyD88 and TLR4 in the LPS-mimetic activity of taxol","volume":"31","author":"Byrd-Leifer","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1365-2125.2011.04111.x","article-title":"Alcoholic neuropathy: possible mechanisms and future treatment possibilities","volume":"73","author":"Chopra","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/ott.s3863","article-title":"Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer","volume":"2","author":"Di Costanzo","year":"2009","journal-title":"Onco Targets Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.neuron.2017.02.005","article-title":"New Horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain","volume":"93","author":"Feldman","year":"2017","journal-title":"Neuron"},{"key":"B10","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12885-018-4869-5","article-title":"Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer","volume":"18","author":"Ghoreishi","year":"2018","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neuropharm.2013.08.016","article-title":"The paradox of paclitaxel neurotoxicity: mechanisms and unanswered questions","volume":"76","author":"Gornstein","year":"2014","journal-title":"Neuropharmacology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12026-022-09307-7","article-title":"Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity","volume":"70","author":"Gupta","year":"2022","journal-title":"Immunol. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0261473","DOI":"10.1371\/journal.pone.0261473","article-title":"Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: a retrospective study in Japan","volume":"16","author":"Hiramoto","year":"2021","journal-title":"PLOS ONE"},{"key":"B14","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.critrevonc.2019.102831","article-title":"Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings","volume":"145","author":"Ibrahim","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1007\/s00415-018-9123-1","article-title":"Alcohol-related peripheral neuropathy: a systematic review and meta-analysis","volume":"266","author":"Julian","year":"2019","journal-title":"J. Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3344\/kjp.24419","article-title":"Effect of glucagon-like peptide-1 receptor agonist on paclitaxel induced neurotoxicity in dorsal root ganglion neuronal cells in vitro","volume":"38","author":"Jung","year":"2025","journal-title":"Korean J. Pain"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jneuroim.2012.09.006","article-title":"Inflammation and oxidative stress induced by cigarette smoke in Lewis rat brains","volume":"254","author":"Khanna","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/toxics9100229","article-title":"Pathomechanisms of paclitaxel-induced peripheral neuropathy","volume":"9","author":"Klein","year":"2021","journal-title":"Toxics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41598-019-57380-0","article-title":"Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: a meta-analysis","volume":"10","author":"Lee","year":"2020","journal-title":"Sci. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2147\/dmso.s403483","article-title":"Association of serum bilirubin levels with Macro- and microvascular complications in Chinese people with type 2 diabetes mellitus: new insight on gender differences","volume":"16","author":"Li","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"B21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/ajco.13923","article-title":"Risk factors for taxane-induced peripheral neuropathy in patients with breast cancer","volume":"20","author":"Liang","year":"2024","journal-title":"Asia Pac J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1327318","DOI":"10.3389\/fonc.2024.1327318","article-title":"Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study","volume":"14","author":"Lixian","year":"2024","journal-title":"Front. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/jco.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1517\/14656566.3.6.755","article-title":"Paclitaxel in cancer therapy","volume":"3","author":"Mekhail","year":"2002","journal-title":"Expert Opin. Pharmacother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s0140-6736(20)31953-x","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11154-012-9231-7","article-title":"Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance","volume":"14","author":"Muris","year":"2013","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA A Cancer J. Clin."},{"key":"B28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: a position statement by the American diabetes association","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.3390\/cells11172647","article-title":"Bilirubin-induced neurological damage: current and emerging iPSC-Derived brain organoid models","volume":"11","author":"Pranty","year":"2022","journal-title":"Cells"},{"key":"B30","article-title":"Alcoholic neuropathy","volume-title":"Statpearls","author":"Sadowski","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12974-020-01818-0","article-title":"The cerebrovascular and neurological impact of chronic smoking on post-traumatic brain injury outcome and recovery: an in vivo study","volume":"17","author":"Sivandzade","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11764-021-01012-y","article-title":"The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors","volume":"16","author":"Timmins","year":"2022","journal-title":"J. Cancer Surviv"},{"key":"B34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.metabol.2005.11.004","article-title":"Body surface area in normal-weight, overweight, and obese adults. A comparison study","volume":"55","author":"Verbraecken","year":"2006","journal-title":"Metabolism"},{"key":"B35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.molmed.2023.01.007","article-title":"The physiology of bilirubin: health and disease equilibrium","volume":"29","author":"Vitek","year":"2023","journal-title":"Trends Mol. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.E14-04-0916","article-title":"How taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2400160","DOI":"10.1200\/go.24.00160","article-title":"Predictive factors of chemotherapy-induced peripheral neuropathy in breast cancer: a decision tree model approach","volume":"10","author":"Wiranata","year":"2024","journal-title":"JCO Glob. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12957-025-03716-2","article-title":"Relationship between BMI and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis","volume":"23","author":"Yanbing","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"112717","DOI":"10.1016\/j.biopha.2022.112717","article-title":"Progress in the treatment of diabetic peripheral neuropathy","volume":"148","author":"Yang","year":"2022","journal-title":"Biomed. Pharmacother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1794696\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:35:36Z","timestamp":1788845736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1794696\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":39,"alternative-id":["10.3389\/fphar.2026.1794696"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1794696","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1794696"}}